"My question to you: how does the current PPS level of a company make their product any better/more saleable?"
The lower PPS does not make its product any better/more saleable. Every trade, however, carries with it a certain degree of risk, which each investor needs to weigh against the potential reward in making the investment. Although the street may have lost confidence, and therefore, greater risk in AMRN, in my estimation, the material increase in ultimate reward outweighs such increased risk.
As another example, I invested heavily in ARIA when it was near $2.00. Undoubtedly, its drug pipeline is much more robust today, and overall, a better-run company, than 24 months ago. But, at these levels and even though a better/more saleable product(s), I'm not necessarily going to make a similarly sized investment, because the up-side return, although likely to be healthy, is now more limited. As such, investor must make its own determination as to the risk associated with the product, but it need consider price in making its investment decision.
Q
News 
Market Data 
Discover 
AI
